Sphere Medical

Ticker: SPHR Exchange: L

Sphere Medical develops and commercialises medical monitoring and diagnostic equipment. Its lead product, Proxima, provides near real-time analysis of blood gases, electrolytes, and metabolites at the patient's bedside within critical care.

Latest Reports

CE Mark opens the door to commercialisation

Published: 30th September 2016

First Belgian order for Proxima confirmed

Published: 30th August 2016

CE Mark expected shortly, launch preparations on track

Published: 21st July 2016

Worthy of further evaluation

Published: 24th February 2016
The finalisation of Proxima 4's development phase opens the way for its commercialisation in Europe, with CE Marking expected mid-2016. The experience gained with Proxima 3 has provided valuable insights that should improve market traction. A launch employing the in-house sales team is expected before year-end but exploiting Proxima 4's potential will require a well-placed existing player. The identification of a suitable marketing partner is a critical next step, with initial discussions underway. Our three phase DCF-based model suggests a valuation of £14.4m, equivalent to 10.2p per share.  Download Now

On the cusp of commercialisation

Published: 22nd September 2016